Advances in the study of A2B adenosine receptor antagonists.
- Author:
Jing WEI
1
;
Wen-Quan YU
;
Qing-Zhi GAO
Author Information
1. School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
- Publication Type:Journal Article
- MeSH:
Adenosine;
pharmacology;
Adenosine A2 Receptor Antagonists;
Adenosine A3 Receptor Antagonists;
Adenosine-5'-(N-ethylcarboxamide);
pharmacology;
therapeutic use;
Animals;
Anti-Asthmatic Agents;
therapeutic use;
Asthma;
drug therapy;
Humans;
Pulmonary Artery;
drug effects;
Structure-Activity Relationship;
Xanthines;
pharmacology
- From:
Acta Pharmaceutica Sinica
2008;43(3):241-246
- CountryChina
- Language:Chinese
-
Abstract:
A2B adenosine receptor is involved in the control of mast cell degranulation, interleukin-8 synthesis and cell growth. A2B adenosine receptor antagonists may serve as novel drugs for asthma, Alzheimer' s disease, cystic fibrosis and type-II diabetes. Therefore, seeking for the highly selective A2B adenosine receptor antagonists has been one of great interest. The molecular basis, structure-activity relationship of selective A2B adenosine receptor antagonists and their interactions with A2B adenosine receptor were reviewed.
